Compare Cloudflare Inc (NET) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cloudflare Inc vs TG Therapeutics Inc — how do they compare? Cloudflare Inc trades at $361.79 (market cap $121.74B), while TG Therapeutics Inc trades at $54.84 (market cap $8.16B). The key difference: Cloudflare Inc is far larger — about 14.9× TG Therapeutics Inc's market cap, and Cloudflare Inc is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cloudflare Inc for 61 Days and TG Therapeutics Inc for 16 Days on average.
| NET | TGTX | |
|---|---|---|
Market Cap | $121.74B | $8.16B |
Volume | 2,433,002 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $359.60 | $59.06 |
52-Week Low | $160.16 | $26.94 |
Typical Hold Time | 61 Days | 16 Days |
Enterprise Value | $121.11B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cloudflare (NET) trades at $357.03, up 4.15% today, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and recent earnings beats. Revenue growth remains robust at $2.17B for 2025, though profitability challenges persist with a -8.21% net margin. Recent product launches including Cloudflare Basin and strategic partnerships with Deutsche Telekom highlight ongoing innovation.
While analyst consensus remains strongly bullish (71% buy ratings), the stock trades above consensus targets at premium valuations (P/S 47.88). Key risks include persistent unprofitability and high valuation multiples. The company's growth trajectory and AI security positioning offer upside potential, but investors face volatility from execution risks and competitive pressures in the cloud infrastructure space.
TG Therapeutics (TGTX) trades at $54.96, up 3.8% with strong fundamentals including 82.37% gross margins and 100.28% ROE, though recent earnings misses and a negative cash flow of -$100.70M in 2025 raise concerns. Technical indicators show bearish momentum with support at $51-$52, while news highlights BRIUMVI's market share gains and potential acquisition interest.
The outlook remains mixed: analyst consensus is bullish with an $80.50 price target, but risks include ongoing litigation, earnings volatility, and competitive pressures. Upside potential hinges on BRIUMVI's continued growth and pipeline advancements, making TGTX a high-risk, high-reward biotech play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cloudflare Inc
Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
Read more on NET →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
